Ulcerative Colitis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Ulcerative Colitis – Pipeline Review, H2 2016’, provides an overview of the Ulcerative Colitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ulcerative Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis

The report reviews pipeline therapeutics for Ulcerative Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ulcerative Colitis therapeutics and enlists all their major and minor projects

The report assesses Ulcerative Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ulcerative Colitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma Plc

AbbVie Inc

Abivax S.A.

Advinus Therapeutics Ltd

Aerpio Therapeutics, Inc.

Am-Pharma B.V.

Amgen Inc.

Aptevo Therapeutics Inc

Arena Pharmaceuticals, Inc.

Atlantic Healthcare Plc

Bionovis SA

Bristol-Myers Squibb Company

Celgene Corporation

Cellceutix Corporation

ChemoCentryx, Inc.

ChironWells GmbH

Coherus BioSciences, Inc.

Cosmo Pharmaceuticals NV

Dr. Falk Pharma GmbH

EA Pharma Co Ltd

Eli Lilly and Company

Enceladus Pharmaceuticals BV

enGene, Inc

Enterome Bioscience SA

Epirus Biopharmaceuticals, Inc.

Flexion Therapeutics, Inc.

Galapagos NV

Genentech, Inc.

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

GW Pharmaceuticals Plc

iCo Therapeutics Inc.

Idera Pharmaceuticals, Inc.

InDex Pharmaceuticals AB

Innovate Biopharmaceuticals, Inc.

INOXIA Lifesciences GmbH

Intas Pharmaceuticals Ltd.

Johnson & Johnson

Kaken Pharmaceutical Co., Ltd.

Kyowa Hakko Kirin Co., Ltd.

LIPID THERAPEUTICS GmbH

Lycera Corp.

Medestea Research & Production S.p.A.

Merck & Co., Inc.

Miyarisan Pharmaceutical Company, Ltd

Momenta Pharmaceuticals, Inc.

Morphotek, Inc.

Mycenax Biotech Inc.

NeuClone Pty Ltd

Oncobiologics, Inc.

OSE Immunotherapeutics

Pfizer Inc.

Pluristem Therapeutics Inc.

ProtAb Ltd

Protagonist Therapeutics Inc.

Protalix BioTherapeutics, Inc.

Qu Biologics Inc.

Re-Pharm Limited

Rebiotix Inc.

Sandoz International GmbH

Seres Therapeutics, Inc.

Shire Plc

Sigmoid Pharma Limited

Stelic Institute & Co., Inc.

Sterna biologicals Gmbh & Co KG

Synergy Pharmaceuticals, Inc.

Synlogic Inc

Takeda Pharmaceutical Company Limited

Therapeutic Proteins International, LLC

Therapix Biosciences Ltd.

Theravance Biopharma, Inc.

Tillotts Pharma AG

TopiVert Ltd

Trino Therapeutics Limited

UCB S.A.

Ventria Bioscience

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Ulcerative Colitis Overview 8

Therapeutics Development 9

Ulcerative Colitis - Therapeutics under Development by Companies 11

Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 18

Ulcerative Colitis - Pipeline Products Glance 19

Ulcerative Colitis - Products under Development by Companies 23

Ulcerative Colitis - Products under Investigation by Universities/Institutes 32

Ulcerative Colitis - Companies Involved in Therapeutics Development 33

Ulcerative Colitis - Therapeutics Assessment 109

Drug Profiles 123

Ulcerative Colitis - Dormant Projects 379

Ulcerative Colitis - Discontinued Products 389

Ulcerative Colitis - Product Development Milestones 391

Appendix 405

List of Tables

List of Tables

Number of Products under Development for Ulcerative Colitis, H2 2016 24

Number of Products under Development for Ulcerative Colitis – Comparative Analysis, H2 2016 25

Number of Products under Development by Companies, H2 2016 27

Number of Products under Development by Companies, H2 2016 (Contd..1) 28

Number of Products under Development by Companies, H2 2016 (Contd..2) 29

Number of Products under Development by Companies, H2 2016 (Contd..3) 30

Number of Products under Development by Companies, H2 2016 (Contd..4) 31

Number of Products under Development by Companies, H2 2016 (Contd..5) 32

Number of Products under Investigation by Universities/Institutes, H2 2016 33

Comparative Analysis by Late Stage Development, H2 2016 34

Comparative Analysis by Clinical Stage Development, H2 2016 35

Comparative Analysis by Early Stage Development, H2 2016 36

Comparative Analysis by Unknown Stage Development, H2 2016 37

Products under Development by Companies, H2 2016 38

Products under Development by Companies, H2 2016 (Contd..1) 39

Products under Development by Companies, H2 2016 (Contd..2) 40

Products under Development by Companies, H2 2016 (Contd..3) 41

Products under Development by Companies, H2 2016 (Contd..4) 42

Products under Development by Companies, H2 2016 (Contd..5) 43

Products under Development by Companies, H2 2016 (Contd..6) 44

Products under Development by Companies, H2 2016 (Contd..7) 45

Products under Development by Companies, H2 2016 (Contd..8) 46

Products under Investigation by Universities/Institutes, H2 2016 47

Ulcerative Colitis – Pipeline by 4D Pharma Plc, H2 2016 48

Ulcerative Colitis – Pipeline by AbbVie Inc, H2 2016 49

Ulcerative Colitis – Pipeline by Abivax S.A., H2 2016 50

Ulcerative Colitis – Pipeline by Advinus Therapeutics Ltd, H2 2016 51

Ulcerative Colitis – Pipeline by Aerpio Therapeutics, Inc., H2 2016 52

Ulcerative Colitis – Pipeline by Am-Pharma B.V., H2 2016 53

Ulcerative Colitis – Pipeline by Amgen Inc., H2 2016 54

Ulcerative Colitis – Pipeline by Aptevo Therapeutics Inc, H2 2016 55

Ulcerative Colitis – Pipeline by Arena Pharmaceuticals, Inc., H2 2016 56

Ulcerative Colitis – Pipeline by Atlantic Healthcare Plc, H2 2016 57

Ulcerative Colitis – Pipeline by Bionovis SA, H2 2016 58

Ulcerative Colitis – Pipeline by Bristol-Myers Squibb Company, H2 2016 59

Ulcerative Colitis – Pipeline by Celgene Corporation, H2 2016 60

Ulcerative Colitis – Pipeline by Cellceutix Corporation, H2 2016 61

Ulcerative Colitis – Pipeline by ChemoCentryx, Inc., H2 2016 62

Ulcerative Colitis – Pipeline by ChironWells GmbH, H2 2016 63

Ulcerative Colitis – Pipeline by Coherus BioSciences, Inc., H2 2016 64

Ulcerative Colitis – Pipeline by Cosmo Pharmaceuticals NV, H2 2016 65

Ulcerative Colitis – Pipeline by Dr. Falk Pharma GmbH, H2 2016 66

Ulcerative Colitis – Pipeline by EA Pharma Co Ltd, H2 2016 67

Ulcerative Colitis – Pipeline by Eli Lilly and Company, H2 2016 68

Ulcerative Colitis – Pipeline by Enceladus Pharmaceuticals BV, H2 2016 69

Ulcerative Colitis – Pipeline by enGene, Inc, H2 2016 70

Ulcerative Colitis – Pipeline by Enterome Bioscience SA, H2 2016 71

Ulcerative Colitis – Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016 72

Ulcerative Colitis – Pipeline by Flexion Therapeutics, Inc., H2 2016 73

Ulcerative Colitis – Pipeline by Galapagos NV, H2 2016 74

Ulcerative Colitis – Pipeline by Genentech, Inc., H2 2016 75

Ulcerative Colitis – Pipeline by Genor BioPharma Co Ltd, H2 2016 76

Ulcerative Colitis – Pipeline by GlaxoSmithKline Plc, H2 2016 77

Ulcerative Colitis – Pipeline by GW Pharmaceuticals Plc, H2 2016 78

Ulcerative Colitis – Pipeline by iCo Therapeutics Inc., H2 2016 79

Ulcerative Colitis – Pipeline by Idera Pharmaceuticals, Inc., H2 2016 80

Ulcerative Colitis – Pipeline by InDex Pharmaceuticals AB, H2 2016 81

Ulcerative Colitis – Pipeline by Innovate Biopharmaceuticals, Inc., H2 2016 82

Ulcerative Colitis – Pipeline by INOXIA Lifesciences GmbH, H2 2016 83

Ulcerative Colitis – Pipeline by Intas Pharmaceuticals Ltd., H2 2016 84

Ulcerative Colitis – Pipeline by Johnson & Johnson, H2 2016 85

Ulcerative Colitis – Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016 86

Ulcerative Colitis – Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 87

Ulcerative Colitis – Pipeline by LIPID THERAPEUTICS GmbH, H2 2016 88

Ulcerative Colitis – Pipeline by Lycera Corp., H2 2016 89

Ulcerative Colitis – Pipeline by Medestea Research & Production S.p.A., H2 2016 90

Ulcerative Colitis – Pipeline by Merck & Co., Inc., H2 2016 91

Ulcerative Colitis – Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016 92

Ulcerative Colitis – Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 93

Ulcerative Colitis – Pipeline by Morphotek, Inc., H2 2016 94

Ulcerative Colitis – Pipeline by Mycenax Biotech Inc., H2 2016 95

Ulcerative Colitis – Pipeline by NeuClone Pty Ltd, H2 2016 96

Ulcerative Colitis – Pipeline by Oncobiologics, Inc., H2 2016 97

Ulcerative Colitis – Pipeline by OSE Immunotherapeutics, H2 2016 98

Ulcerative Colitis – Pipeline by Pfizer Inc., H2 2016 99

Ulcerative Colitis – Pipeline by Pluristem Therapeutics Inc., H2 2016 100

Ulcerative Colitis – Pipeline by ProtAb Ltd, H2 2016 101

Ulcerative Colitis – Pipeline by Protagonist Therapeutics Inc., H2 2016 102

Ulcerative Colitis – Pipeline by Protalix BioTherapeutics, Inc., H2 2016 103

Ulcerative Colitis – Pipeline by Qu Biologics Inc., H2 2016 104

Ulcerative Colitis – Pipeline by Re-Pharm Limited, H2 2016 105

Ulcerative Colitis – Pipeline by Rebiotix Inc., H2 2016 106

Ulcerative Colitis – Pipeline by Sandoz International GmbH, H2 2016 107

Ulcerative Colitis – Pipeline by Seres Therapeutics, Inc., H2 2016 108

Ulcerative Colitis – Pipeline by Shire Plc, H2 2016 109

Ulcerative Colitis – Pipeline by Sigmoid Pharma Limited, H2 2016 110

Ulcerative Colitis – Pipeline by Stelic Institute & Co., Inc., H2 2016 111

Ulcerative Colitis – Pipeline by sterna biologicals Gmbh & Co KG, H2 2016 112

Ulcerative Colitis – Pipeline by Synergy Pharmaceuticals, Inc., H2 2016 113

Ulcerative Colitis – Pipeline by Synlogic Inc, H2 2016 114

Ulcerative Colitis – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 115

Ulcerative Colitis – Pipeline by Therapeutic Proteins International, LLC, H2 2016 116

Ulcerative Colitis – Pipeline by Therapix Biosciences Ltd., H2 2016 117

Ulcerative Colitis – Pipeline by Theravance Biopharma, Inc., H2 2016 118

Ulcerative Colitis – Pipeline by Tillotts Pharma AG, H2 2016 119

Ulcerative Colitis – Pipeline by TopiVert Ltd, H2 2016 120

Ulcerative Colitis – Pipeline by Trino Therapeutics Limited, H2 2016 121

Ulcerative Colitis – Pipeline by UCB S.A., H2 2016 122

Ulcerative Colitis – Pipeline by Ventria Bioscience, H2 2016 123

Assessment by Monotherapy Products, H2 2016 124

Number of Products by Stage and Target, H2 2016 126

Number of Products by Stage and Mechanism of Action, H2 2016 130

Number of Products by Stage and Route of Administration, H2 2016 135

Number of Products by Stage and Molecule Type, H2 2016 137

Ulcerative Colitis – Dormant Projects, H2 2016 394

Ulcerative Colitis – Dormant Projects (Contd..1), H2 2016 395

Ulcerative Colitis – Dormant Projects (Contd..2), H2 2016 396

Ulcerative Colitis – Dormant Projects (Contd..3), H2 2016 397

Ulcerative Colitis – Dormant Projects (Contd..4), H2 2016 398

Ulcerative Colitis – Dormant Projects (Contd..5), H2 2016 399

Ulcerative Colitis – Dormant Projects (Contd..6), H2 2016 400

Ulcerative Colitis – Dormant Projects (Contd..7), H2 2016 401

Ulcerative Colitis – Dormant Projects (Contd..8), H2 2016 402

Ulcerative Colitis – Dormant Projects (Contd..9), H2 2016 403

Ulcerative Colitis – Discontinued Products, H2 2016 404

Ulcerative Colitis – Discontinued Products (Contd..1), H2 2016 405

List of Figures

List of Figures

Number of Products under Development for Ulcerative Colitis, H2 2016 24

Number of Products under Development for Ulcerative Colitis – Comparative Analysis, H2 2016 25

Number of Products under Development by Companies, H2 2016 26

Number of Products under Investigation by Universities/Institutes, H2 2016 33

Comparative Analysis by Late Stage Development, H2 2016 34

Comparative Analysis by Clinical Stage Development, H2 2016 35

Comparative Analysis by Early Stage Products, H2 2016 36

Assessment by Monotherapy Products, H2 2016 124

Number of Products by Top 10 Targets, H2 2016 125

Number of Products by Stage and Top 10 Targets, H2 2016 125

Number of Products by Top 10 Mechanism of Actions, H2 2016 129

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 129

Number of Products by Top 10 Routes of Administration, H2 2016 134

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 134

Number of Products by Top 10 Molecule Types, H2 2016 136

Number of Products by Stage and Top 10 Molecule Types, H2 2016 136

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports